Skip to main contentAI and Advanced
/
GLAXO · NSEMarket ticker unavailable · configure an authorised index feed
GL
NSE · Equity shares · Biotechnology & Drugs55.00 · 1.95%
GlaxoSmithKline Pharmaceuticals GLAXO
NSE:INR 2,878
BSE:INR 2,583
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for GLAXO
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 2,823
Day rangeINR 2,755.9 — INR 2,878
52-week rangeINR 2,088.1 — INR 3,120.7
Volume85,458
Market cap44,539.37
P/E38.86
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)3,821.67
Net Income (INR Cr)1,035.98
Rev Growth (5 Year %)5.49
EPS Growth (5 Year %)29.24
P/E Ratio38.86
EPS60.26
Research path: Interpret GlaxoSmithKline Pharmaceuticals's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
GLAXOGlaxoSmithKline Pharmaceuticals1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 4,323.87 | 4,108.07 | 3,556.62 |
| Accumulated Depreciation Total | -319.92 | -295.62 | -283.13 |
| Cash Equivalents | 997 | 435 | 0 |
| Other Liabilities Total | 260.07 | 249.11 | 247.56 |
| Accrued Expenses | 92.1 | 155.98 | 114.21 |
| Common Stock Total | 169.41 | 169.41 | 169.41 |
| Other Current Assets Total | 28.14 | 26.39 | 23.93 |
| Prepaid Expenses | 19.07 | 18.89 | 20.62 |
| Total Assets | 4,323.87 | 4,108.07 | 3,556.62 |
| Current Portof LT Debt/Capital Leases | 16 | 7.46 | 12.2 |
| Cash | 105.05 | 103.85 | 64.17 |
| Total Equity | 2,267.42 | 1,951.31 | 1,777.64 |
| Long Term Investments | 1.55 | 0.81 | 0.94 |
| Retained Earnings(Accumulated Deficit) | 2,098.01 | 1,781.9 | 1,608.23 |
| Total Common Shares Outstanding | 16.94 | 16.94 | 16.94 |
| Property/Plant/Equipment Total-Gross | 626.37 | 579.48 | 593.86 |
| Tangible Book Valueper Share Common Eq | 133.46 | 114.4 | 103.54 |
| Total Liabilities | 2,056.45 | 2,156.75 | 1,778.98 |
| Total Debt | 33.27 | 9.95 | 18.67 |
| Short Term Investments | 1,653.42 | 1,959.26 | 1,792.65 |
| Cashand Short Term Investments | 2,755.48 | 2,498.1 | 1,856.82 |
| Total Receivables Net | 333.9 | 379.32 | 363.13 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Accounts Receivable-Trade Net | 287.08 | 301.5 | 231.07 |
| Property/Plant/Equipment Total-Net | 306.44 | 283.86 | 310.73 |
| Total Current Liabilities | 1,779.1 | 1,905.15 | 1,524.95 |
| Total Inventory | 469.61 | 487.19 | 533.91 |
| Accounts Payable | 570.22 | 708.25 | 625.41 |
| Other Currentliabilities Total | 1,100.78 | 1,033.47 | 773.13 |
| Total Long Term Debt | 17.27 | 2.49 | 6.47 |
| Intangibles Net | 6.56 | 13.33 | 23.55 |
| Other Long Term Assets Total | 189.14 | 185.68 | 191.7 |
| Note Receivable-Long Term | 213.98 | 214.5 | 231.27 |
| Total Current Assets | 3,606.2 | 3,409.88 | 2,798.42 |
| Capital Lease Obligations | 17.27 | 2.49 | 6.47 |
| Long Term Debt | Not available | 0 | Not available |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio2.09
Price to Sale Ratio11.65
Growth
Debt 5Yr CAGR %-0.79
Margins
Operating Margin 12m32.53
Operating Margin 5y Avg25.38
Net Profit Margin 12m27.01
Net Profit Margin 5y20.18
Yield
Dividend Yield %2.22
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk25.07
Analyst consensus
ConsensusBuy
Consensus score2.00
Analyst opinions4
Strong Sell count0
Sell count0
Hold count1
Buy count2
Strong Buy count1
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 75.00%
- FII
- 4.79%
- MF
- 4.87%
- Other
- 15.34%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade - Markets MojoMarket news · 4 Jun 2026, 9:21 am
Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade Markets Mojo
Glaxosmithkline Pharmaceuticals Ltd is Rated Sell - Markets MojoMarket news · 3 Jun 2026, 10:54 am
Glaxosmithkline Pharmaceuticals Ltd is Rated Sell Markets Mojo
GSK Pharma recommends ₹57 dividend, sets AGM date - scanx.tradeMarket news · 3 Jun 2026, 3:32 am
GSK Pharma recommends ₹57 dividend, sets AGM date scanx.trade
Five Consecutive Losses Push Glaxosmithkline Pharmaceuticals Ltd to a New 52-Week Low - Markets MojoMarket news · 2 Jun 2026, 4:43 pm
Five Consecutive Losses Push Glaxosmithkline Pharmaceuticals Ltd to a New 52-Week Low Markets Mojo
Markets Rally, But Glaxosmithkline Pharmaceuticals Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off - Markets MojoMarket news · 1 Jun 2026, 4:06 pm
Markets Rally, But Glaxosmithkline Pharmaceuticals Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off Markets Mojo
GSK Pharma Compliance Officer resigns effective August 5, 2026 - scanx.tradeMarket news · 30 May 2026, 12:30 pm
GSK Pharma Compliance Officer resigns effective August 5, 2026 scanx.trade
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.57.0000 per share(570%)Final Dividend
- board MeetingsAudited Results & Dividend
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for GlaxoSmithKline Pharmaceuticals
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- GLAXO
- BSE Code
- 500660
Questions
Stock FAQ
What is the symbol and ISIN of GlaxoSmithKline Pharmaceuticals?
GlaxoSmithKline Pharmaceuticals has the symbol GLAXO and ISIN - INE159A01016.
What is the current price of GlaxoSmithKline Pharmaceuticals?
GlaxoSmithKline Pharmaceuticals is currently trading at INR 2,878.00.
What are the year high and year low of GlaxoSmithKline Pharmaceuticals?
GlaxoSmithKline Pharmaceuticals has a year high of INR 3,120.70 and a year low of INR 2,088.10.
What is the market capitalization of GlaxoSmithKline Pharmaceuticals?
GlaxoSmithKline Pharmaceuticals has a market capitalization of INR 44,539.37 crore.
What is the P/E ratio of GlaxoSmithKline Pharmaceuticals?
GlaxoSmithKline Pharmaceuticals has a P/E ratio of 38.86.
What is the dividend yield of GlaxoSmithKline Pharmaceuticals?
GlaxoSmithKline Pharmaceuticals has a dividend yield of 2.22%.
How is the financial performance of GlaxoSmithKline Pharmaceuticals based on revenue, net income, and EPS?
GlaxoSmithKline Pharmaceuticals has revenue of INR 3,821.67 crore, net income of INR 1,035.98 crore, and EPS of INR 62.16.
What is the book value of GlaxoSmithKline Pharmaceuticals?
GlaxoSmithKline Pharmaceuticals has a book value of NA.
What is the debt-to-equity ratio of GlaxoSmithKline Pharmaceuticals?
GlaxoSmithKline Pharmaceuticals has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of GlaxoSmithKline Pharmaceuticals?
GlaxoSmithKline Pharmaceuticals has a price-to-book ratio of NA and a price-to-sales ratio of 11.65.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.